
Tvardi Therapeutics: Pioneering breakthrough medicines for cancers and chronic diseases since 2017.
Tvardi Therapeutics is a clinical-stage biotechnology company founded in 2017 and based in Houston, Texas. The company is dedicated to developing breakthrough medicines targeting diverse cancers, chronic inflammatory diseases, and fibrotic diseases. Tvardi's innovative approach focuses on creating a new class of therapies, including their novel STAT3 inhibitor, TTI-101, which is currently undergoing clinical trials.
Tvardi Therapeutics has made significant strides in the biotech industry, including presenting their Phase 1 clinical trial results for liver cancer at the ASCO Gastrointestinal Cancers Symposium. The company has attracted notable leadership, with Sujal Shah appointed as Chairman and Shaheen Wirk joining the Board of Directors. Tvardi continues to participate in prominent industry conferences, such as the Cowen 44th Annual Health Care Conference, showcasing their commitment to advancing medical research and treatment options.

Iterion Therapeutics
Indalo Therapeutics

Starton Therapeutics
startontx.com

Tavros Therapeutics

Star Therapeutics

Tavotek Biotherapeutics
tavotek.com

Therini Bio
therinibio.com

Stellanova Therapeutics
stellanovatx.com

Treadwell Therapeutics
treadwelltx.com

Elgia Therapeutics
Blade Therapeutics

Tachyon Therapeutics
tachyontx.com

MDI Therapeutics

Trevarx Biomedical
trevarx.com

Stingray Therapeutics
stingraytx.com

Thetis Pharmaceuticals
thetispharma.com

Adcentrx Therapeutics
adcentrx.com

TORL BioTherapeutics
torlbio.com

Avstera Therapeutics
avstera.com

Tigris Pharmaceuticals
tigrispharma.com
Tvardi Therapeutics' most recent funding round was for $72.4M (USD) in June 2021.
As of Jun 15, 2021, Tvardi Therapeutics has disclosed funding of $81.4M (USD).